Evidence map›Paper›PMID 37024807›Full record

ArticleBMC infectious diseases2023

The impact of HIV infection on clinical presentation and mortality among persons with hepatocellular carcinoma in Kampala, Uganda.

Sara K Nsibirwa, Jim Aizire, Julie Nabweteme Mugerwa, David L Thomas, Ponsiano Ocama, Gregory D Kirk

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Sara K NsibirwaHIV and HCC in Uganda (H²U) Consortium, Kampala, Uganda. snsibirwa@idi.co.ug.
Jim AizireHIV and HCC in Uganda (H²U) Consortium, Kampala, Uganda.
Julie Nabweteme MugerwaHIV and HCC in Uganda (H²U) Consortium, Kampala, Uganda.
David L ThomasHIV and HCC in Uganda (H²U) Consortium, Kampala, Uganda.
Ponsiano OcamaHIV and HCC in Uganda (H²U) Consortium, Kampala, Uganda.
Gregory D KirkHIV and HCC in Uganda (H²U) Consortium, Kampala, Uganda.
Malaria Consortium · UGHutchinson Centre Research Institute in Uganda · UGJohns Hopkins University · USMakerere University · UG

Funding

The Role of HIV Infection in the Etiology and Clinical Manifestations of Hep CarcinomaU54CA190165 · NCI · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 2014 to 2019
$4.2M
Patient-Oriented Research and Mentorship in HIV and Non-Communicable DiseasesK24AI118591 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 2015 to 2019
$766k
National Institute of Allergy and Infectious Diseases K24-AI118591NCI NIH HHS U54 CA190165NCI NIH HHS U54-CA190165NIAID NIH HHS K24 AI118591
6 · The paper itself

Abstract

backgroundHIV infection is associated with more rapid progression of some comorbidities. This study assessed the impact of HIV-infection on the presentation and outcome of HCC.

methodsHCC patients attending the Mulago National Referral Hospital in Uganda were enrolled into a natural history study of HCC between March 2015 and February 2019. Standardized methods were used to collect clinical, ultrasound and laboratory data at enrolment. HCC cases were confirmed and enrolled based on a combination of clinical, ultrasound, tumor marker and pathology data. Follow-up contact was made at one, three, six, and twelve months post-enrolment to determine vital status. Symptoms and signs at diagnosis and subsequent survival were compared by HIV status. Kaplan Meier curves were used to assess HCC survival.

resultsOf 441 persons with HCC, 383 (87.0%) died within 12 months following HCC diagnosis. The median (IQR) survival was 42 (20, 106) days. HIV infection was present in 79 (18%) cases. After adjusting for baseline demographic and clinical characteristics, HIV infection was associated with increased mortality but only among those with severe HIV-associated immunosuppression (CD4 count < 200 cells per cubic milliliter), aHR (95% C) = 2.12 (1.23-3.53), p = 0.004, and not among PLWH with ≥ 200 CD4 cells per cubic milliliter, aHR (95% C) = 1.15 (0.82-1.60), p = 0.417.

conclusionAmong relatively young Ugandans, HCC is a devastating disease with rapid mortality that is especially rapid among people living with HIV(PLWH). HIV was associated with slightly higher mortality, notably among PLWH with lower CD4 cell counts. As a substantial majority of PLWH diagnosed with HCC were engaged in HIV care, further investigation should determine the effectiveness of incorporating screening and early identification of HCC among high-risk individuals into existing HIV care programs. Concurrent with growing access to curative localized treatment for HCC in sub-Saharan Africa, leveraging HIV care infrastructure affords opportunities for earlier HCC intervention.

Indexed as

Carcinoma, HepatocellularHIV InfectionsLiver NeoplasmsAfrica South of the SaharaCD4 Lymphocyte CountHumansUgandaHepatocellular carcinoma (HCC)Human immunodeficiency virusMortalitySub-saharan Africa

Identifiers

PMID37024807
PMCPMC10080890
OpenAlexW4362665413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.